Free Trial

Prenetics Global Q3 2023 Earnings Report

Prenetics Global logo
$5.64 +0.16 (+2.92%)
(As of 12/20/2024 05:16 PM ET)

Prenetics Global Earnings Headlines

Prenetics’ IM8, University of Oxford begin space experiment
AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
See More Prenetics Global Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prenetics Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prenetics Global and other key companies, straight to your email.

About Prenetics Global

Prenetics Global (NASDAQ:PRE), a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.

View Prenetics Global Profile

More Earnings Resources from MarketBeat

Upcoming Earnings